pyrroles has been researched along with Nail Diseases in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| de Miquel, VA; Esquembre, AC; Hoyos, CL; Leal, RP; Mejías, FP; Spröhnle, JL | 1 |
| Elewski, B; Kaur, M; Lan, S; Merola, JF; Tallman, A; Tatulych, S | 1 |
| Cho, S; Huh, CH; Kwon, O; Lee, JS; Park, HS; Yoon, HS | 1 |
| Dhayalan, A; King, BA | 1 |
| Aranegui, B; Bueno, C; Espinosa Lara, P; Jiménez Reyes, J; Vargas-Machuca, I | 1 |
| Ferreira, R; Ferreira, SB; Jaller, AM; Jaller, JA; Jaller, JJ; Jaller-Char, JJ; Scheinberg, M | 1 |
| Armand, JP; Escudier, B; Faivre, S; Raymond, E; Robert, C | 1 |
| Autier, J; Mateus, C; Robert, C; Spatz, A; Wechsler, J | 1 |
| Burgin, S; Heidary, N; Naik, H | 1 |
2 review(s) available for pyrroles and Nail Diseases
| Article | Year |
|---|---|
[Cutaneous side effects of sorafenib and sunitinib].
Topics: Acrodermatitis; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Hair Diseases; Humans; Indoles; Nail Diseases; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; raf Kinases; Receptors, Vascular Endothelial Growth Factor; Skin; Sorafenib; Sunitinib | 2008 |
Chemotherapeutic agents and the skin: An update.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites; Antineoplastic Agents; Benzamides; Benzenesulfonates; Cetuximab; Drug Eruptions; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Fusion Proteins, bcr-abl; Gefitinib; Hair Diseases; Humans; Imatinib Mesylate; Indoles; Mucous Membrane; Nail Diseases; Niacinamide; Phenylurea Compounds; Piperazines; Platinum Compounds; Proteasome Inhibitors; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction; Skin; Skin Diseases; Sorafenib; Sunitinib; Taxoids | 2008 |
1 trial(s) available for pyrroles and Nail Diseases
| Article | Year |
|---|---|
Efficacy of tofacitinib for the treatment of nail psoriasis: Two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Double-Blind Method; Female; Humans; Male; Middle Aged; Nail Diseases; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Time Factors; Treatment Outcome; Young Adult | 2017 |
6 other study(ies) available for pyrroles and Nail Diseases
| Article | Year |
|---|---|
Nail toxicity induced by Pemigatinib.
Topics: Humans; Morpholines; Nail Diseases; Pyrimidines; Pyrroles | 2022 |
Nail involvement in patients with moderate-to-severe alopecia areata treated with oral tofacitinib.
Topics: Administration, Oral; Adult; Alopecia Areata; Female; Humans; Male; Middle Aged; Nail Diseases; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies | 2018 |
Tofacitinib Citrate for the Treatment of Nail Dystrophy Associated With Alopecia Universalis.
Topics: Adult; Alopecia; Female; Humans; Janus Kinases; Male; Nail Diseases; Nails; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles | 2016 |
Yellowish nail pigmentation caused by sunitinib.
Topics: Aged; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Nail Diseases; Pigmentation Disorders; Pyrroles; Risk Assessment; Sunitinib | 2016 |
Recovery of nail dystrophy potential new therapeutic indication of tofacitinib.
Topics: Adult; Alopecia; Female; Humans; Male; Nail Diseases; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome | 2017 |
Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors?
Topics: Antineoplastic Agents; Benzenesulfonates; Hemorrhage; Humans; Indoles; Nail Diseases; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib | 2005 |